Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Two IMP4297 Formulations in Healthy Males
NCT04351165Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of senaparib in solid tumor (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Maximum Plasma Concentration at 3 months, Area Under the Curve to Last Timepoint at 3 months and 1 more. Started Oct 2020; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04351165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351165.